Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT03449381 trial: what clinicians have said so far
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
- NCT03449381 ↗
- Completed
- Boehringer Ingelheim
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT03449381 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03449381 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 (Brigimadlin) in Patients With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Neoplasms
- Interventions
- BI 907828
- Arms
- Dose Escalation · Experimental
- Dose Expansion · Experimental
- Enrollment
- 266
- Primary outcomes
- Phase Ia- Maximum tolerated dose (MTD) based on number of patients with dose limiting toxicities (DLTs) during first treatment cycle
- Phase Ib - Progression-free survival
- Phase Ia - Number of patients with DLTs during first treatment cycle (21 days, Arm A; 28 days, Arm B)
- Phase Ib - Number of patients with DLTs during the first treatment cycle
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 20, 2018
- Primary completion
- Nov 13, 2025
- Results posted
- No
- Registry record
- NCT03449381 · updated Mar 31, 2026
Publications
linked from the registry- Gollner A, Rudolph D, Weyer-Czernilofsky U, Baumgartinger R, Jung P, Weinstabl H, Ramharter J, Grempler R, Quant J, Rinnenthal J, Perez Pitarch A, Golubovic B, Gerlach D, Bader G, Wetzel K, Otto S, Mandl C, Boehmelt G, McConnell DB, Kraut N, Sini P. Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2-p53 Antagonist Suitable for Intermittent Dose Schedules. Mol Cancer Ther. 2024 Dec 3;23(12):1689-1702. doi: 10.1158/1535-7163.MCT-23-0783. PubMed 39259562
- LoRusso P, Yamamoto N, Patel MR, Laurie SA, Bauer TM, Geng J, Davenport T, Teufel M, Li J, Lahmar M, Gounder MM. The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study. Cancer Discov. 2023 Aug 4;13(8):1802-1813. doi: 10.1158/2159-8290.CD-23-0153. PubMed 37269344